Whole-genome profiling highlights the molecular complexity underlying eccentric cardiac hypertrophy

Therapeutic Advances in Cardiovascular Disease

Volumn 8, Issue 3, 2014, Pages 97-118

  Barnes, Justin ^a   Pat, Betty ^b   Chen, Yuan Wen ^b   Powell, Pamela C ^b   Bradley, Wayne E ^b   Zheng, Junying ^b   Karki, Amrit ^c   Cui, Xiangqin ^c   Guichard, Jason ^b   Wei, Chih Chang ^c   Collawn, James ^d   Dell’italia, Louis J ^e  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

heart failure; left ventricular function; pressure overload; volume overload

Indexed keywords

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; AORTOCAVAL FISTULA; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; GENOME ANALYSIS; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE OVERLOAD; HEART VENTRICLE HYPERTROPHY; MALE; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRANSVERSE AORTIC CONSTRICTION;

EID: 84904767014     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944714527490     Document Type: Article

References (86)

1. Barry W. (1994) Mechanisms of Immune-Mediated Myocyte Injury. Circulation 89: 2421–2432.
2. Blankesteijn W. van de Schans V. Ter Horst P. Smits J. (2008) The Wnt/Frizzled/Gsk-3 beta pathway: a novel therapeutic target for cardiac hypertrophy. Trends Pharmacol Sci 29: 175–180.
3. Bommarito A. Richiusa P. Carissimi E. Pizzolanti G. Rodolico V. Zito G. et al. (2011) BRAFV600E mutation, TIMP-1 upregulation, and NF-kappaB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer 18: 669–685.
4. Borer J. Bonow R. (2003) Contemporary approach to aortic and mitral regurgitation. Circulation 108: 2432–2438.
5. Brower G. Henegar J. Janicki J. (1996) Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload. Am J Physiol 271: H2071–H2078.
6. Cerrone M. Noorman M. Lin X. Chkourko H. Liang F. van der Nagel R. et al. (2012) Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency. Cardiovasc Res 95: 460–468.
7. Chen Y. Pat B. Gladden J. Zheng J. Powell P. Wei C. et al. (2011) Dynamic molecular and histopathological changes in the extracellular matrix and inflammation in the transition to heart failure in isolated volume overload. Am J Physiol Heart Circ Physiol 300: H2251–H2260.
8. Chen Y. Pat B. Zheng J. Cain L. Powell P. Shi K. et al. (2010) Tumor necrosis factor-alpha produced in cardiomyocytes mediates a predominant myocardial inflammatory response to stretch in early volume overload. J Mol Cell Cardiol 49: 70–78.
9. Cheng X. Obata K. Kuzuya M. Izawa H. Nakamura K. Asai E. et al. (2006) Elastolytic cathepsin induction / activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 48: 979–987.
10. Colombatti A. Spessotto P. Doliana R. Mongiat M. Bressan G. Esposito G. (2011) The emilin / multimerin family. Front Immunol 2: 93.
11. Da Costa Martins P. de Windt L. (2012) MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res 93: 563–572.
12. Das A. Uhler M. Hajra A. (2000) Molecular cloning and expression of mammalian peroxisomal trans-2-enoyl-coenzyme A reductase CDNAs. J Biol Chem 275: 24333–24340.
13. Das S. Aiba T. Rosenberg M. Hessler K. Xiao C. Quintero P. et al. (2012) Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling. Circulation 126: 2208–2219.
14. Dell'Italia L. Balcells E. Meng Q. Su X. Schultz D. Bishop S. et al. (1997) Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol 273: H961–H970.
15. Duisters R. Tijsen A. Schroen B. Leenders J. Lentink V. van der Made I. et al. (2009) Mir-133 and Mir-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104: 170–178.
16. Ellis J. Mentock S. Depetrillo M. Koves T. Sen S. Watkins S. et al. (2011) Mouse cardiac acyl coenzyme A synthetase 1 deficiency impairs fatty acid oxidation and induces cardiac hypertrophy. Mol Cell Biol 31: 1252-1262.
17. Finck B. Kelly D. (2002) Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 34: 1249–1257.
18. Foltz D. Jansen L. Black B. Bailey A. Yates J. III Cleveland D. (2006) The human CENP-A centromeric nucleosome-associated complex. Nat Cell Biol 8: 458–469.
19. Fujimoto N. Terlizzi J. Aho S. Brittingham R. Fertala A. Oyama N. et al. (2006) Extracellular matrix protein 1 inhibits the activity of matrix metalloproteinase 9 through high-affinity protein / protein interactions. Exp Dermatol 15: 300–307.
20. Galaktionov K. Beach D. (1991) Specific activation of CDC 25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 67: 1181–1194.
21. Gibson M. Finnis M. Kumaratilake J. Cleary E. (1998) Microfibril-associated glycoprotein-2 (MAGP-2) is specifically associated with fibrillin-containing microfibrils but exhibits more restricted patterns of tissue localization and developmental expression than its structural relative MAGP-1. J Histochem Cytochem 46: 871–886.
22. Grossman W. Jones D. Mclaurin L. (1975) Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56: 56–64.
23. Gruneberg U. Neef R. Honda R. Nigg E. Barr F. (2004) Relocation of Aurora B from centromeres to the central spindle at the metaphase to anaphase transition requires MKLP2. J Cell Biol 166: 167–172.
24. Guerrero P. Schuessler R. Davis L. Beyer E. Johnson C. Yamada K. et al. (1997) Slow ventricular conduction in mice heterozygous for a Connexin 43 null mutation. J Clin Invest 99: 1991–1998.
25. Harper J. Adami G. Wei N. Keyomarsi K. Elledge S. (1993) The P 21 CDK-interacting protein CIP 1 is a potent inhibitor of G 1 cyclin-dependent kinases. Cell 75: 805–816.
26. Hayata N. Fujio Y. Yamamoto Y. Iwakura T. Obana M. Takai M. et al. (2008) Connective tissue growth factor induces cardiac hypertrophy through AKT signaling. Biochem Biophys Res Commun 370: 274–278.
27. Hederstedt L. Rutberg L. (1981) Succinate dehydrogenase - a comparative review. Microbiol Rev 45: 542–555.
28. Hirose K. Kawashima T. Iwamoto I. Nosaka T. Kitamura T. (2001) MGCRACGAP is involved in cytokinesis through associating with mitotic spindle and midbody. J Biol Chem 276: 5821–5828.
29. Hou G. Mulholland D. Gronska M. Bendeck M. (2000) Type VIII collagen stimulates smooth muscle cell migration and matrix metalloproteinase synthesis after arterial injury. Am J Pathol 156: 467–476.
30. Houser S. Margulies K. Murphy A. Spinale F. Francis G. Prabhu S. et al. (2012) Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res 111: 131–150.
31. Ito W. Schafer H. Bhakdi S. Klask R. Hansen S. Schaarschmidt S. et al. (1996) Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc Res 32: 294–305.
32. Jane-Lise S. Corda S. Chassagne C. Rappaport L. (2000) The extracellular matrix and the cytoskeleton in heart hypertrophy and failure. Heart Fail Rev 5: 239–250.
33. Jiang W. Jimenez G. Wells N. Hope T. Wahl G. Hunter T. et al. (1998) PRC1: a human mitotic spindle-associated CDK substrate protein required for cytokinesis. Mol Cell 2: 877–885.
34. Kadenbach B. Merle P. (1981) On the function of multiple subunits of cytochrome C oxidase from higher eukaryotes. FEBS Lett 135: 1–11.
35. Kaufman P. Kobayashi R. Kessler N. Stillman B. (1995) The P 150 and P 60 subunits of chromatin assembly factor I: a molecular link between newly synthesized histones and DNA replication. Cell 81: 1105–1114.
36. Kim H. Lee M. Lee S. Park B. Koh W. Lee D. et al. (2009) Cancer-upregulated gene 2 (CUG2), a new component of centromere complex, is required for kinetochore function. Mol Cells 27: 697–701.
37. Kitamura K. Uyeda K. (1987) The mechanism of activation of heart fructose 6-phosphate,2-kinase:fructose-2,6-bisphosphatase. J Biol Chem 262: 679–681.
38. Koff A. Giordano A. Desai D. Yamashita K. Harper J. Elledge S. et al. (1992) Formation and activation of a cyclin E–CDK2 complex during the G 1 phase of the human cell cycle. Science 257: 1689–1694.
39. Kothapalli D. Grotendorst G. (2000) CTGF modulates cell cycle progression in CAMP-arrested NRK fibroblasts. J Cell Physiol 182: 119–126.
40. Kuwahara F. Kai H. Tokuda K. Takeya M. Takeshita A. Egashira K. et al. (2004) Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 43: 739–745.
41. Laczy B. Hill B. Wang K. Paterson A. White C. Xing D. et al. (2009) Protein O-GLCNacylation: a new signaling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol 296: H13–H28.
42. Li Y. McTiernan C. Feldman A. (2000) Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46: 214–224.
43. Lien C. Schebesta M. Makino S. Weber G. Keating M. (2006) Gene expression analysis of zebrafish heart regeneration. PLoS Biol 4: e260.
44. Lister K. Autelitano D. Jenkins A. Hannan R. Sheppard K. (2006) Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1. Cardiovasc Res 70: 555–565.
45. Lloyd-Jones D. Adams R. Brown T. Carnethon M. Dai S. de Simone G. et al. (2010) Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121: e46–e215.
46. Lorell B. Carabello B. (2000) Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102: 470–479.
47. Lu A. Feng H. Wang P. Han D. Chen X. Zheng M. (2012) Emerging roles of the ribonucleotide reductase M 2 in colorectal cancer and ultraviolet-induced DNA damage repair. World J Gastroenterol 18: 4704–4713.
48. Maeda S. Matsuoka I. Iwamoto T. Kurose H. Kimura J. (2005) Down-regulation of Na+/Ca2+ exchanger by fluvastatin in rat cardiomyoblast H9C2 cells: involvement of Rhob in Na+/Ca2+ exchanger MRNA stability. Mol Pharmacol 68: 414–420.
49. Maiorano D. Lutzmann M. Mechali M. (2006) MCM proteins and DNA replication. Curr Opin Cell Biol 18: 130–136.
50. Malumbres M. (2011) Physiological relevance of cell cycle kinases. Physiol Rev 91: 973–1007.
51. Marber M. Rose B. Wang Y. (2011) The P 38 mitogen-activated protein kinase pathway - a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol 51: 485–490.
52. Marsh S. Dell'italia L. Chatham J. (2009) Interaction of diet and diabetes on cardiovascular function in rats. Am J Physiol Heart Circ Physiol 296: H282–H292.
53. Mayer U. Kohfeldt E. Timpl R. (1998) Structural and genetic analysis of laminin–nidogen interaction. Ann N Y Acad Sci 857: 130–142.
54. Miyazaki H. Oka N. Koga A. Ohmura H. Ueda T. Imaizumi T. (2006) Comparison of gene expression profiling in pressure and volume overload-induced myocardial hypertrophies in rats. Hypertens Res 29: 1029–1045.
55. Molkentin J. (2000) Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res 87: 731–738.
56. Molnar J. Fong K. He Q. Hayashi K. Kim Y. Fong S. et al. (2003) Structural and functional diversity of lysyl oxidase and the LOX-like proteins. Biochim Biophys Acta 1647: 220–224.
57. Most P. Seifert H. Gao E. Funakoshi H. Volkers M. Heierhorst J. et al. (2006) Cardiac S100a1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 114: 1258–1268.
58. Nagatsu M. Zile M. Tsutsui H. Schmid P. Defreyte G. Cooper G. et al. (1994) Native beta-adrenergic support for left ventricular dysfunction in experimental mitral regurgitation normalizes indexes of pump and contractile function. Circulation 89: 818–826.
59. Narouz-Ott L. Maurer P. Nitsche D. Smyth N. Paulsson M. (2000) Thrombospondin-4 binds specifically to both collagenous and non-collagenous extracellular matrix proteins via its C-terminal domains. J Biol Chem 275: 37110–37117.
60. Oka T. Komuro I. (2008) Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J 72(Suppl. A): A13–A16.
61. Patel M. Korotchkina L. (2006) Regulation of the pyruvate dehydrogenase complex. Biochem Soc Trans 34: 217–222.
62. Perry G. Wei C. Hankes G. Dillon S. Rynders P. Mukherjee R. et al. (2002) Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol 39: 1374–1379.
63. Procaccio V. de Sury R. Martinez P. Depetris D. Rabilloud T. Soularue P. et al. (1998) Mapping to 1q23 of the human gene (NDUFS2) encoding the 49-KDA subunit of the mitochondrial respiratory complex I and immunodetection of the mature protein in mitochondria. Mamm Genome 9: 482–484.
64. Reddy V. Harskamp R. van Ginkel M. Calhoon J. Baisden C. Kim I. et al. (2008) Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-AKT-dependent NF-kappaB activation. J Cell Physiol 215: 697–707.
65. Ruzicka M. Keeley F. Leenen F. (1994) The renin–angiotensin system and volume overload-induced changes in cardiac collagen and elastin. Circulation 90: 1989–1996.
66. Ryan T. Rothstein E. Aban I. Tallaj J. Husain A. Lucchesi P. et al. (2007) Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload. J Am Coll Cardiol 49: 811–821.
67. Schulte J. Seidl M. Nunes F. Freese C. Schneider M. Schmitz W. et al. (2012) CREB critically regulates action potential shape and duration in the adult mouse ventricle. Am J Physiol Heart Circ Physiol 302: H1998–H2007.
68. Shiratori A. Okumura K. Nogami M. Taguchi H. Onozaki T. Inoue T. et al. (1995) Assignment of the 49-kDa (PRIM1) and 58-kDa (PRIM2A and PRIM2B) subunit genes of the human dna primase to chromosome bands 1q44 and 6p11.1-P12. Genomics 28: 350–353.
69. Stewart J. Jr Massey E. Fix C. Zhu J. Goldsmith E. Carver W. (2010) Temporal alterations in cardiac fibroblast function following induction of pressure overload. Cell Tissue Res 340: 117-126.
70. Strom C. Kruhoffer M. Knudsen S. Stensgaard-Hansen F. Jonassen T. Orntoft T. et al. (2004) Identification of a core set of genes that signifies pathways underlying cardiac hypertrophy. Comp Funct Genomics 5: 459–470.
71. Stumpe K. Solle H. Klein H. Kruck F. (1973) Mechanism of sodium and water retention in rats with experimental heart failure. Kidney Int 4: 309–317.
72. Taggart C. Lowe G. Greene C. Mulgrew A. O'Neill S. Levine R. et al. (2001) Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem 276: 33345–33352.
73. Timpl R. Sasaki T. Kostka G. Chu M. (2003) Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 4: 479–489.
74. Toischer K. Rokita A. Unsold B. Zhu W. Kararigas G. Sossalla S. et al. (2010) Differential cardiac remodeling in preload versus afterload. Circulation 122: 993–1003.
75. Ueland T. Yndestad A. Oie E. Florholmen G. Halvorsen B. Froland S. et al. (2005) Dysregulated osteoprotegerin / rank ligand/rank axis in clinical and experimental heart failure. Circulation 111: 2461–2468.
76. Vairapandi M. Balliet A. Hoffman B. Liebermann D. (2002) GADD45B and GADD45G are CDC2/CYCLINB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress. J Cell Physiol 192: 327–338.
77. van der Slot A. Zuurmond A. Bardoel A. Wijmenga C. Pruijs H. Sillence D. et al. (2003) Identification of PLOD 2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 278: 40967–40972.
78. Varo N. Iraburu M. Varela M. Lopez B. Etayo J. Diez J. (2000) Chronic AT (1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 35: 1197–1202.
79. Wagner R. Tabibiazar R. Powers J. Bernstein D. Quertermous T. (2004) Genome-wide expression profiling of a cardiac pressure overload model identifies major metabolic and signaling pathway responses. J Mol Cell Cardiol 37: 1159–1170.
80. Walter M. Plotnick M. Schechter N. (1996) Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin. Arch Biochem Biophys 327: 81–88.
81. Weber K. (2004) From inflammation to fibrosis: a stiff stretch of highway. Hypertension 43: 716–719.
82. Wei C. Chen Y. Powell L. Zheng J. Shi K. Bradley W. et al. (2012) Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss. PloS ONE 7: e40110.
83. Wei C. Lucchesi P. Tallaj J. Bradley W. Powell P. Dell'italia L. (2003) Cardiac interstitial bradykinin and mast cells modulate pattern of LV remodeling in volume overload in rats. Am J Physiol Heart Circ Physiol 285: H784–H792
84. Wight T. (2002) Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 14: 617–623.
85. Xi Y. Wu G. Yang L. Han K. Du Y. Wang T. et al. (2009) Increased late sodium currents are related to transcription of neuronal isoforms in a pressure-overload model. Eur J Heart Fail 11: 749–757.
86. Zhao Y. Lyons C. Jr Xiao A. Templeton D. Sang Q. Brew K. et al. (2008) Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion. Biochem Biophys Res Commun 369: 1215-1220.